Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

Launched by SADAT CITY UNIVERSITY · Jul 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two medications, nitazoxanide and rifaximin, to see which one works better for adults with diarrhea caused by irritable bowel syndrome (IBS). The goal is to find out if nitazoxanide can help reduce symptoms more effectively over a two-week treatment period and how well it works in the long run, over 10 weeks after treatment. The trial is currently looking for participants aged 18 and older who have been experiencing active IBS symptoms for at least two weeks.

To join the study, participants should have frequent diarrhea and moderate to severe abdominal pain. Certain health issues, like liver disease or recent surgeries, may prevent someone from participating. Those interested can expect to take one of the medications for two weeks and then be monitored for an additional 10 weeks to see how well their symptoms improve. This research is important as it could help identify better treatment options for those struggling with IBS-related diarrhea.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 years of age or older.
• • Patients suffering from diarrhea-predominant IBS according to Rome III criteria.
• • Active symptoms for at least 2 weeks
• • Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) abdominal pain score of \> 3.0 on a 0-to-10-point scale and Stool Consistency: at least one stool with a consistency of Type 6 or Type 7 Bristol stool score (BSS) on at least 2 days per week
• • Report no restriction whatsoever on their diet.
• Exclusion Criteria:
• • Presence of liver disease, malignancy, severe malabsorption, bedridden, endocrinological disorders, or severe chronic obstructive pulmonary disease.
• • Patients who have undergone abdominal surgeries except for appendectomy and/or cholecystectomy and/or hysterectomy.
• • Patients who consumed any medications that may affect bowel function within the last 2 weeks such as antibiotics, probiotics, prebiotics, antispasmodics, antidiarrheals, narcotics, or any other medication that may alter bowel function
• • Patients on antidepressants or antipsychotics starting within the last six weeks before eligibility check.